Citing toxicity concerns, Boehringer Ingelheim drops short-lived IPF pact — keeping $1B+ in its pocket

Boehringer Ingelheim has quietly killed a short-lived deal that it was prepared to spend $1.25 billion on, returning an early-stage drug to its Korean biotech partner.